HSIC

Henry Schein, Inc.

• Simply Wall St·1d ago

  Henry Schein’s Board Overhaul and Bergman Exit Might Change The Case For Investing In HSIC

• Dow Jones·6d ago

  Henry Schein to Reduce Board Size as Chairman Retires, Several Members Opt Out of Re-Election

• Seeking Alpha·6d ago

  Henry Schein shrinks board as long-serving chairman retires

• Dow Jones·6d ago

  Henry Schein Price Target Cut to $90.00/Share From $100.00 by Evercore ISI Group

• Dow Jones·6d ago

  Henry Schein Is Maintained at Outperform by Evercore ISI Group

• Benzinga·6d ago

  Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $90

• TipRanks·6d ago

  Henry Schein price target lowered to $90 from $100 at Evercore ISI

• TipRanks·6d ago

  Henry Schein to reduce size of board of directors following annual meeting

• Reuters·6d ago

  Henry Schein publishes 2025 annual report, posts $13.2 billion net sales

• Benzinga·6d ago

  Henry Schein Chairman Stanley M. Bergman to Retire After 44 Years, Board Shrinks to 10 Members

• Reuters·6d ago

  Henry Schein announces annual shareholder meeting

• Reuters·6d ago

  Henry Schein names Bergman chairman emeritus as longtime CEO retires from board

• Barron‘s·04/07 19:08

  Williams, Henry Schein, and 3 Other Bargain Stocks From a Veteran Value Fund Manager

• Simply Wall St·04/03 04:55

  Assessing Henry Schein (HSIC) Valuation As Recent Share Price Moves Draw Fresh Attention

• TipRanks·03/31 10:40

  Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Spyre Therapeutics (SYRE) and Henry Schein (HSIC)